JAPAN-CORN-STARCH
17.2.2017 01:54:37 CET | Business Wire | Press release
Japan Corn Starch Co., Ltd. (Minato-ku, Tokyo; Soichiro Kurachi, president. Hereby, “Japan Corn Starch” or “the company”), the largest corn wet miller in Japan has been pursuing excellent flavor in the increasingly diverse food industry, and conducting research to find the perfect balance of fructose and glucose in high-fructose corn syrup (HFCS), used in a variety of soft drinks. The company successfully developed and obtained patent for a new product, “HFCS 70” that maintains the body equal to fructose glucose liquid sugar used in many soft drinks while having the sharp sweetness of fructose, and is about to release the product.
Since its development 50 years ago, there were only three varieties of HFCS until this year, glucose-fructose liquid sugar, fructose-glucose liquid sugar, and high-fructose liquid sugar, commoditization of which made their differentiation difficult. However, by introducing HFCS 70 into the market, the company expects to overturn the stereotypes in the HFCS industry and create a new wind in the industry.
Japan Corn Starch’s new product, HFCS 70 maintains the body while realizing a high level of sharp sweetness. This allows the product to create a flavor different from fructose glucose liquid sugar, high fructose liquid sugar, or crystalline fructose that are mainstream in the soft drink industry, and help the development of delicious drinks with a new type of sweetness. In addition, because HFCS maintains the body while realizing a high level of sharp sweetness, it can be used in products such as highly refreshing and filling jellies.
Japan Corn Starch has obtained licenses such as the first FSSC22000 and HACCP in the industry and ISO22301, which is the international standard for business continuity management system (BCMS). Furthermore, the company has been making efforts such as radiation dose measurement of each product using high-performance equipment, and quantification of odor using odor identification devices. Thus the company is fully equipped for stable distribution of products.
As a comprehensive producer of starch-related products, Japan Corn Starch will continue its commitment to offer reliable, safe, and high quality products that cater our clients’ every need through its thoroughgoing distribution system.
About the Company
Company name: Japan Corn Starch Co., Ltd.
President: Soichiro
Kurachi
Head office: Akasaka Inter City 3F, 1-11-44 Akasaka, Minato
Ward, Tokyo, 107-0052
Tel: +81-3-5570-7000 (operator)
Fax:
+81-3-5570-7001
Mail: corn@japan-cornstarch.com
URL:
http://www.nihon-cornstarch.com/english
Founded:
1867
View source version on businesswire.com: http://www.businesswire.com/news/home/20170216006427/en/
Contact:
Japan Corn Starch Co., Ltd.
Kazuki Hashimoto, +81-566-42-3129
Public
Relations
corn@japan-cornstarch.com
http://www.nihon-cornstarch.com/english
fax:
+81-3-5570-7001
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom